Last reviewed · How we verify
NCT04395534
Non-microradical Resection Margin as a Predictor for Recurrence After Complete Mesocolic Excision
trial testing Complete mesocolic excision in Colon Cancer in 276 participants. Completed in 15 March 2020.
15 March 2020
Quick facts
| Lead sponsor | Claus Anders Bertelsen, PhD, MD |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 276 |
| Start date | 1 June 2008 |
| Primary completion | 15 March 2020 |
| Estimated completion | 15 March 2020 |
Drugs / interventions tested
- Complete mesocolic excision
Conditions studied
- Colon Cancer — all drugs for Colon Cancer →
Sponsor
Claus Anders Bertelsen, PhD, MD
Who can join
18 and older, any sex, with Colon Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study aim to investigate the value of the current definition of microradical resection margin in colon cancer. Is the distance from tumor tissue to resection margin and the site of any clinically prognostic importance if complete mesocolic excision has been performed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04395534
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Complete mesocolic excision
Trials testing the same drug.
- NCT03774134 — Five Year Oncological Outcome After CME for Sigmoid Colon Cancer · active not recruiting
- NCT03754075 — Five Year Oncological Outcome After CME for Right-sided Colon Cancer · unknown
Other recruiting trials for Colon Cancer
Currently open trials in the same condition.
- NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
- NCT07279077 — Node-Sparing Low-Dose Radiotherapy Concurrent With Chemotherapy and PD-1 Inhibitor in pMMR/MSS High-Risk Locally Advance · Phase 2 · recruiting
- NCT07205965 — The Effect of Acceptance and Commitment Approach-Based Psychoeducation in Cancer Survivors · NA · active not recruiting
- NCT07285356 — Study to Evaluate the Use of Surgical Gloves for the Prevention of Oxaliplatin-Induced Peripheral Neuropathy · NA · recruiting
- NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
Other Claus Anders Bertelsen, PhD, MD trials
Trials by the same sponsor.
- NCT06287671 — Colorectal Omics and OfCS Proteoglycans · recruiting
- NCT04311099 — Optimal Peripheral Nerve Block After Minimally Invasive Colon Surgery · Phase 4 · completed
- NCT04407117 — Appendicitis During the National Lockdown During the COVID-19 Pandemic · completed
- NCT04477824 — Is Acute Appendicitis Still a Clinical Diagnosis? · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04395534 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Claus Anders Bertelsen, PhD, MD
- Last refreshed: 20 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04395534.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing